This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Csl Innovation Pty Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Innovations by Paolo Rossato in Cardiovascular Treatment
Introduction
Paolo Rossato is an innovative inventor based in Marburg, Germany. He has made significant contributions to the field of medicine, particularly in the treatment of complications associated with sickle cell disease. His work focuses on developing methods that can improve the quality of life for patients suffering from this condition.
Latest Patents
One of Paolo Rossato's notable patents is titled "Methods of treating or preventing a cardiovascular system complication of sickle cell disease with an anti-G-CSFR antibody." This patent outlines methods for treating, preventing, or delaying the progression of complications associated with sickle cell disease. The method involves administering a compound that inhibits granulocyte colony stimulating factor (G-CSF) signaling and/or G-CSF activity. This innovative approach has the potential to significantly impact patient care.
Career Highlights
Paolo Rossato is currently associated with Csl Innovation Pty Ltd, where he continues to work on groundbreaking research and development in the medical field. His dedication to innovation is evident in his patent work and ongoing research efforts.
Collaborations
Paolo collaborates with esteemed colleagues, including Lisa Margareta Lindqvist and Andreas Gille. These partnerships enhance the research and development process, fostering an environment of creativity and innovation.
Conclusion
Paolo Rossato's contributions to the field of medicine, particularly through his patent on treating sickle cell disease complications, highlight his role as a leading inventor. His work not only showcases his innovative spirit but also holds promise for improving patient outcomes in the future.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile